US 12,000,829 B2
Selection of patients for combination therapy
Peter Ordentlich, Lexington, MA (US); Lei Wang, Waltham, MA (US); Serap Sankoh, Waltham, MA (US); and Michael Meyers, Waltham, MA (US)
Assigned to Syndax Pharmaceuticals, Inc., Waltham, MA (US)
Appl. No. 17/053,559
Filed by SYNDAX PHARMACEUTICALS, INC., Waltham, MA (US)
PCT Filed May 7, 2019, PCT No. PCT/US2019/031210
§ 371(c)(1), (2) Date Nov. 6, 2020,
PCT Pub. No. WO2019/217484, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/668,055, filed on May 7, 2018.
Prior Publication US 2021/0239697 A1, Aug. 5, 2021
Int. Cl. G01N 33/569 (2006.01); A61K 9/00 (2006.01); A61K 31/4406 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)
CPC G01N 33/56977 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/4406 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); G01N 33/56972 (2013.01); G01N 33/57423 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); G01N 2333/70535 (2013.01); G01N 2333/70539 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01)] 18 Claims
 
1. A method of selecting a patient for combination therapy comprising entinostat and an anti-PD-1 antibody comprising:
providing a peripheral blood sample obtained from the patient, wherein the patient is diagnosed with a cancer;
measuring the number of cells in the peripheral blood sample which are CD14-positive, HLA-DR-high, and CD16-negative;
measuring the number of total peripheral blood mononuclear cells in the peripheral blood sample; and
administering the combination therapy if the percentage of the CD14-positive, HLA-DR-high, and CD16-negative cells relative to total peripheral blood mononuclear cells is greater than a pre-determined percentage; wherein the pre-determined percentage is at least about 5%.